Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsCreative Biolabs will work with you to speed development and unleash the potential of your discovery. With our extensive experience and advanced platform, including many antibody products, we are driven by science and can solve complex large molecule challenges. We are committed to providing a number of antibodies with high levels of specificity, sensitivity, and lot-to-lot consistency for our worldwide customers.
Platelet-derived growth factor receptors (PDGFRs) are a type of cell surface receptors that can specifically bind to a variety of platelet-derived growth factors (PDGFs). Two kinds of PDGFRs have been defined in previous studies, PDGFR alpha, and PDGFR beta. The data indicate that PDGFRs are responsible for regulating the process of angiogenesis and cell transformation in many tissues. Meanwhile, the expression of PDGFR has been confirmed in a battery of cells, especially in tumor cells. A lot of evidence has been accumulated that blockade of PDGFR should be an attractive strategy for controlling the development of a number of tumors, such as ovarian cancer, fibrosarcoma, and gliomas. Furthermore, recent researchers have developed a series of anti-PDGFR antibodies to improve the effectiveness of chemotherapy. For example, monoclonal antibodies to human PDGFRα have been generated to prevent the binding with PDGF. The results suggest that such antibodies are useful especially in soft tissue sarcoma and several solid tumors. Additionally, an anti-PDGFRβ antibody that inhibiting of vascular endothelial growth factors (VEGF) and PDGF together can efficiently interpret the procedure of angiogenesis and blood vessel maturation in solid tumor cells. As a result, the anti-PDGFR antibody has been regarded as an important drug target in cancer therapy.
Fig.1 Schematic representation of PDGFs and PDGFRs. (Vincenzi, 2017)
Recent studies have shown that PDGFR plays a critical role in mediating the survival and progression of many diseases, including several human malignant tumors, and its antibody could provide a novel therapeutic approach. In this condition, a series of anti-PDGFR antibodies targeting different kinds of tumors have been generated and widely used for pre-clinical or clinical studies. Nowadays, Creative Biolabs has established a full range of anti-PDGFR antibody discovery and development services to meet the requirement of our clients. In general, our service begins with identifying an antigen, and suitable antigens will be injected into a host animal to trigger an immune response to develop antibody mixtures. These antibodies will be selected by specific state-of-art technologies basing on the desired type of antibodies. For example, polyclonal antibodies are usually derived from the serum, while monoclonal antibodies require hybridoma technology in mice. Currently, we have developed several anti-PDGFR antibodies for our client. The safety of these antibodies has been evaluated by immunological methods, such as enzyme-linked immunosorbent assay (ELISA) and immunoblotting. In a recent study, a fully human monoclonal antibody to human PDGFRα blocking both PDGF-AA and PDGF-BB ligands have been generated. The in vivo antitumor activity has been tested in glioblastoma xenograft tumor models in C57BL/6 mice.
Fig.2 Custom Anti-PDGFR Antibody Service.
Creative Biolabs aims to educate about the development of antibodies. With the broadest range of antibody generation platforms, we offer custom anti-PDGFR antibody development to accelerate your research and diagnostic project. Whether you need custom antibody or help with an antibody project, our expertise assured that your project is in capable hands. For more detailed information, please feel free to contact us or send us an inquiry.
Reference
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
